The End Brain Cancer Initiative is seeking brain cancer patients to share video testimonials describing how Belay Diagnostics' liquid biopsy tests helped them.
The End Brain Cancer Initiative is seeking brain cancer patients to share video testimonials describing how Belay Diagnostics' liquid biopsy tests helped them.
Learn about the Phase 2 clinical trial of Immune12 for glioblastoma (GBM) patients in Australia, managed by the End Brain Cancer Initiative.
Share your story! The End Brain Cancer Initiative is conducting patient interviews and video testimonials on Belay Diagnostics' CSF liquid biopsy tests.
Discover how Patrick "Paddy" O'Donnell's journey inspires the future of AI and personalized treatments for glioblastoma brain cancer. Learn more at EBCI.
ROADS Trial Phase 3 results show tile-based radiation significantly improves overall survival & tumor control for newly diagnosed brain metastases.
Imaging Biometrics reports Phase 1 results for oral Gallium Maltolate (GaM) in recurrent glioblastoma (GBM), showing high tolerance & extended survival.
A phase 2 Immune12 trial is recruiting glioblastoma patients in Australia, with pre-qualification through EBCI. Immune12 is a marine biologic therapeutic.
Revolutionary GBM trial explores a new treatment strategy for glioblastoma, aiming to improve outcomes and bring hope to patients.
IDH mutations in brain cancer: what they mean for glioma diagnosis, prognosis, and targeted treatment options.
Exvade’s Tumor Monorail for glioblastoma enables real-time tumor access, repeat sampling, and safer treatment monitoring in brain cancer.
Discover new treatments for Primary Central Nervous System Lymphoma (PCNSL). Learn about clinical trials and research from the End Brain Cancer Initiative.
Glioblastoma patients: take a 15-minute confidential GBM online survey to share your experience, shape future treatments, and support brain cancer research.
